Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice

Chamorro-de-Vega, E.; Gimenez-Manzorro, A.; Rodriguez-Gonzalez, C. G.; Escudero-Vilaplana, V.; Collado Borrell, R.; Ibanez-Garcia, S.; Lallana Sainz, E.; Lobato Matilla, E.; Lorenzo-Pinto, A.; Manrique-Rodriguez, S.; Fernandez-Llamazares, C. M.; Marzal-Alfaro, M.; Ribed, A.; Romero Jimenez, R. M.; Sarobe Gonzalez, C.; Herranz, A.; Sanjurjo, M.

期刊名称Annals of Pharmacotherapy
作者Chamorro-de-Vega, E.; Gimenez-Manzorro, A.; Rodriguez-Gonzalez, C. G.; Escudero-Vilaplana, V.; Collado Borrell, R.; Ibanez-Garcia, S.; Lallana Sainz, E.; Lobato Matilla, E.; Lorenzo-Pinto, A.; Manrique-Rodriguez, S.; Fernandez-Llamazares, C. M.; Marzal-Alfaro, M.; Ribed, A.; Romero Jimenez, R. M.; Sarobe Gonzalez, C.; Herranz, A.; Sanjurjo, M.
印刷ISSN1060-0280
电子ISSN1542-6270
发表时间2016-07-14
DOI10.1177/1060028016659306

发现好书期刊，享受阅读乐趣

Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice